Home・Akciju saraksts・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Slēgts

SektorsVeselības aprūpe

13.14 -2.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.92

Max

13.45

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.2M -13M
Pārdošana	-2.8M 14M
EPS	-0.67
Peļņas marža	-76.292
Darbinieki	120
EBITDA	-30M -39M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+48.81% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 13. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-22M 400M
Iepriekšējā atvēršanas cena	15.59
Iepriekšējā slēgšanas cena	13.14

Ziņu noskaņojums

By Acuity

75%

25%

317 / 340 Rangs Healthcare

ENANTA PHARMACEUTICALS INC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 20:06 UTC

Enanta Pharmaceuticals is trading lower amid mixed market sentiment following a reported decline in U.S. retail sales for July.

2026. g. 13. aug. 19:36 UTC

Enanta Pharmaceuticals Inc is trading higher, remaining above its 20-day moving average, despite no specific company news identified for the price movement.

2026. g. 11. aug. 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, reflecting broader market declines. The stock reached a session low earlier but has since recovered slightly.

2026. g. 5. aug. 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower, reflecting broader market sentiment amid disappointing ADP employment data showing a rise of only 44,000 jobs in July.

2026. g. 4. aug. 19:46 UTC

Enanta Pharmaceuticals Inc shares are higher, buoyed by a decline in crude oil prices that eases inflation concerns. No specific company news was identified.

2026. g. 3. aug. 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

2026. g. 31. jūl. 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

2026. g. 30. jūl. 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

2026. g. 29. jūl. 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

2026. g. 28. jūl. 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

2026. g. 27. jūl. 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

2026. g. 24. jūl. 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

2026. g. 21. jūl. 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

2026. g. 20. jūl. 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Salīdzinājums

Cenas izmaiņa

ENANTA PHARMACEUTICALS INC Prognoze

Cenas mērķis

By TipRanks

48.81% augšup

Prognoze 12 mēnešiem

Vidējais 20 USD 48.81%

Augstākais 20 USD

Zemākais 20 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ENANTA PHARMACEUTICALS INC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ENANTA PHARMACEUTICALS INC — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

317 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.